Report Raises Concerns About HEP C Drugs
"Hepatitis C affects more than 2 million people in the United States and millions more worldwide. The disease can also be difficult to diagnosis, persisting for decades without symptoms and eventually progressing to cirrhosis of increasing severity."
"Statements made by the US Food and Drug Administration (FDA) in October 2016, in which they note the first major safety problem linked to nine new direct-acting antiviral drugs for hepatitis C, including sofosbuvir (SOVALDI), ledipasvir-sofosbuvir (HARVONI), and simeprevir (OLYSIO). While each drug has demonstrated success at suppressing hepatitis C virus to undetectable levels in most patients, they have also been linked to the reactivation of hepatitis B, with severe health consequences, including liver transplant and death."